KRAS and cancer: Messenger ribonucleic acid (mRNA)-5671/V941 is a novel mRNA vaccine encoding mutant KRAS which is being studied in patients with KRASmu cancers in phase I clinical trial (NCT03948763), with or without Pembrolizumab.